Healthcare

Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2026, after the close of market on Thursday, July 30, 2026.

Castle Biosciences, Inc.July 9, 20262 min read
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026

About this update from Castle Biosciences, Inc.

FRIENDSWOOD, Texas, July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2026, after the close of market on Thursday, July 30, 2026. Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Webcast Details The live webcast can be accessed here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=gbu0MZxe , or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/ . Please access the webcast at least 10 minutes before the start time. A replay of the webcast will be available following its conclusion. There will be a brief Question and Answer session following management commentary. About Castle Biosciences Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes. We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit  www.CastleBiosciences.com and connect with us on  LinkedIn , Instagram , Facebook and  X . DecisionDx-Melanoma, DecisionDx-CM Seq , i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc. Investor Contact: Camilla Zuckero [email protected] Media Contact: Allison Marshall [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/castle-biosciences-to-release-second-quarter-2026-financial-results-and-host-webcast-on-thursday-july-30-2026-302821112.html

View stock analysis, news, and events for Castle Biosciences, Inc.

Castle Biosciences, Inc.Castle BiosciencesCSTLimproving healthfinancial resultspatient carepatient outcomesdisease management

More from Castle Biosciences, Inc.

All Castle Biosciences, Inc. news →